21 September, 2017
Barrington Strategic Wealth Mgmt Group Incorporated Lc has invested 0.37% of its portfolio in AbbVie Inc (NYSE:ABBV).
Analysts expect AbbVie Inc (NYSE:ABBV) to report $1.37 EPS on October, 27.They anticipate $0.16 EPS change or 13.22 % from last quarter's $1.21 EPS. Institutional owners hold 70.90% stake in the company while Insiders ownership held at 0.10%. Verde Servicos Internacionais S.A.'s holdings in AbbVie were worth $2,377,000 at the end of the most recent quarter.
Other investment firms and many large funds also purchased and unloaded stocks of the company. Staton Financial Advisors LLC boosted its position in shares of AbbVie by 8.8% in the 1st quarter. The Stocks were purchased at a consensus cost of $70.45 for a share, with a total value of $281,800.00. after the closing of the acquisition, the director has an ownership of 15,498 company stock worth at $1,091,834.10. Tortoise Mngmt Ltd Liability Corp holds 0.01% in AbbVie Inc (NYSE:ABBV) or 323 shares. Washington Trust Bank increased its stake in shares of AbbVie by 1.8% in the 1st quarter. Aristotle Capital Management LLC now owns 4,526,623 shares of the company's stock worth $294,954,000 after buying an additional 154,719 shares in the last quarter. Tradewinds Capital Management LLC now owns 2,269 shares of the company's stock valued at $148,000 after purchasing an additional 1,057 shares in the last quarter. The stock declined 0.22% or $0.19 reaching $87.23 per share.
A number of equities analysts recently weighed in on the company. Deutsche Bank AG reiterated a "hold" rating and issued a $66.00 price objective (up previously from $65.00) on shares of AbbVie in a research note on Monday, July 17th. The stock has "Buy" rating by SunTrust on Wednesday, July 22. BidaskClub downgraded AbbVie from a "strong-buy" rating to a "buy" rating in a report on Friday, July 28th. Jefferies reiterated a "buy" recommendation and fixed a $107.00 price target (up prior from $94.00) on stocks of AbbVie in a study note published on Fri, Sep 15th. Leerink Swann reissued a "market perform" rating on shares of AbbVie in a research report on Thursday, June 22nd. Seven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of "Buy" and an average target price of $82.38. The shares were sold at an average price of $71.00, for a total transaction of $13,712,301.00. Manning And Napier Ltd Liability Company holds 258,056 shares or 0.16% of its portfolio. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
In related news, insider Henry O. Gosebruch sold 18,000 shares of the business's stock in a transaction on Monday, July 31st.
The difference of 52 week low value as well as 52 week high value and the current price of the stock suggests the next move of the shares. Over the last quarter, insiders have sold 373,191 shares of company stock valued at $26,598,305. The disclosure for this sale can be found here. The company recorded a rise in short interest of 0.21% as of the latest report on August 31, 2017. Abbvie Inc has $100.0 highest and $6 lowest target. Cornerstone Ptnrs Ltd holds 0.05% in AbbVie Inc (NYSE:ABBV) or 14,435 shares. About 2.19 million shares traded.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. Private Advisor Ltd invested in 163,596 shares or 0.32% of the stock. $4.67 million worth of AbbVie Inc (NYSE:ABBV) was sold by GONZALEZ RICHARD A on Friday, May 19. AbbVie had a return on equity of 150.27% and a net margin of 24.77%. The corporation posted $1.42 EPS for the period, reaching the Thomson Reuters' average forecast of $1.40 by $0.02.
As we sail into the last quarter of the calendar year, investors may be looking to see what has gone right and what has gone wrong so far this year. Barton Invest Management owns 0.17% invested in AbbVie Inc (NYSE:ABBV) for 8,994 shares. The ex-dividend date of this dividend is Thursday, October 12th. This represents a $2.56 annualized dividend and a yield of 2.93%. First Financial Corp acquired 9,430 shares as Abbvie Inc (ABBV)'s stock rose 6.17%. Abbvie Inc now has $139.34B valuation. The Firm is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. The correct version of this report can be accessed at https://weekherald.com/2017/09/21/abbvie-inc-abbv-stake-lessened-by-hartford-investment-management-co.html. The Company's products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
